|
|
|
06.02.26 - 18:03
|
Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital (Business Wire)
|
|
|
Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMFPARIS--(BUSINESS WIRE)--Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN code: FR0010609263, Ticker: ALMKT
Website: www.maunakeatech.com
Date
Number of shares comprising
the capital in circulation
Total number of voting rights
Gross Total (1)
Net Total (2)
January 31, 2026
192,202,823
193,286,360
193,286,360
(1) The gross number of voting rights (or "theoretical" voting rights) serves as the basis for calculating the thresholds. In accordance with Article 223-11 of the General Regulations of the AMF, this number is calculated on the basis of all shares carrying voting rights, including shares without voting rights.
(2) The net number of voting rights (or voting rights "exercisable in General Meeting") is calculated without considering the shares with suspended voting rights. It is published for proper public information in accordance with the AMF recomm...
|
|
|
|
|
06.02.26 - 16:30
|
Börsentitanen unter der Lupe: Novo Nordisk unter Druck, Amazon investiert, Apple als Anker, Eli Lilly vs. Novo. Mastercard, LVMH (BRN)
|
|
|
Im Gespräch mit Rainer Waldhauser (MoneyMindSet) und wikifolio-Trader von "Börsentitanen" geht es um echte Burggräben: nicht traden, sondern sich langfristig an Unternehmen beteiligen. Alphabet bleibt für ihn die KI-Leitaktie, weil Google-Macht und Gemini zusammenspielen. Amazon sieht er trotz Kurs-Schock als Langfrist-Wette: 200 Mrd. USD Investitionen für 2026 in KI, Chips, Robotik und Satelliten sollen Rendite bringen. Apple ist sein Stabilitätsanker: Das iPhone 17 soll Rekorde bringen, China komme zurück. Bei LVMH sieht er trotz -5% Umsatz und -13% Nettogewinn wieder bessere Signale, Luxus kann Preise anheben. Mastercard ist für ihn ein Dauerläufer ohne Kreditrisiko und verdient an jeder Kartenzahlung. Novo Nordisk hält er nach dem Absturz für unterbewertet: KGV 12,2 und Dividende 4,2%, Einstieg lieber in Tranchen. Eli Lilly bleibt für ihn der stärkste Player, aber teuer (KGV 45) und politisch anfällig. Hier geht es zum wikifolio: https://go.brn-ag.de/502...
|
|
|
|
|
|
|
|
|
06.02.26 - 08:03
|
FR Regulatory News: BIOSYNEX SA (EQS)
|
|
|
BIOSYNEX SA: CHEMBIO DIAGNOSTIC SYSTEMS INC., FILIALE DE BIOSYNEX, REÇOIT UNE SUBVENTION DE $1,8 MILLION DE CARB-X POUR LE DÉVELOPPEMENT D’UN TEST DE DIAGNOSTIC RAPIDE DE LA FIEVRE TYPHOIDE...
|
|
|
06.02.26 - 07:36
|
Sensorion Announces its Participation in the Association for Research in Otolaryngology ARO 49th Annual Midwinter Meeting (Business Wire)
|
|
|
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent loss disorders, today announces its participation in the Association for Research in Otolaryngology (ARO) 49th Annual Midwinter Meeting, taking place on February 7-11, 2026, in San Juan, Puerto Rico.
Arnaud Giese, Ph.D., Group Leader for Animal Pharmacology Platform at Sensorion, will present the following presentation at the ARO meeting:
Presentation type: Podium Presentation
Title: SENS-601, a Novel Adeno Associated Vector-Based Gene Therapy as a Treatment for the Autosomal Recessive Non-Syndromic Deafness 1A (DFNB1A)
Date: Sunday, February 8, 2026
Time: 11:30am ET
Room: 209ABC, Podium 6: OTOF Gene Therapy Trial Updates and New Targets: GJB2 & STRC
About Sensorion Sensorion is a pioneering clinical-stage biotech company, which specializes in the development of novel therapies to re...
|
|
|
|
|
|
|
|
|
|
|
|
|
04.02.26 - 22:03
|
Inventiva to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 (GlobeNewswire EN)
|
|
|
Daix (France), New York (United States), February 4, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that CEO Andrew Obenshain has been invited to participate in a fireside chat at the upcoming Guggenheim Emerging Outlook: Biotech Summit 2026. The conference is being held February 11-12, 2026 at the Lotte New York Palace in New York City. Inventiva leadership will also hold one-on-one meetings during the conference....
|
|
|
|
|
|
|
04.02.26 - 06:09
|
TAGESVORSCHAU: Termine am 4. Februar 2026 (DPA-AFX)
|
|
|
FRANKFURT (dpa-AFX) - Wirtschafts- und Finanztermine am Mittwoch, den 4. Februar 2026^TERMINE UNTERNEHMEN06:45 CHE: UBS, Jahreszahlen07:00 CHE: Novartis, Jahreszahlen07:00 FRA: Credit Agricole, Jahreszahlen07:00 NOR: ......
|
|
|
03.02.26 - 18:03
|
ABL Diagnostics: Sale of a New Block of Shares by Its Main Shareholder ABL (Business Wire)
|
|
|
WOIPPY, France--(BUSINESS WIRE)--Regulatory News:
ABL Diagnostics (Paris:ABLD) announces that its main shareholder, Advanced Biological Laboratories (ABL), a Luxembourg-based diagnostics company, has filed information with the French Financial Markets Authority (AMF) via ONDE, the centralized information filing system, regarding the sale of a new block of ABL Diagnostics shares as part of an over-the-counter transaction with a private third party.
The filing relating to this sale can be viewed in the AMF's database of decisions and financial information (BDIF) at the following address: https://bdif.amf-france.org/fr/details/2026DD1092130.
With the support of its main shareholder, ABL, ABL Diagnostics is continuing its efforts to enhance its visibility among all stakeholders (investors, partners, customers, and employees).
About ABL Diagnostics (ABLD)
ABL Diagnostics (ABLD) is an international company that specializes in innovative molecular biology tests and global solutions for its customers:
Molecular ...
|
|
|
03.02.26 - 18:03
|
MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital (Business Wire)
|
|
|
Article 223-16 of the General Regulations of the Financial Markets Authority
(AMF - Autorité des Marchés Financiers)LYON, France--(BUSINESS WIRE)--$MAAT #InvestorRelations--Regulatory News:
MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, today published the number of shares comprising the share capital and the total number of voting rights (Article L. 233-8 of the French Commercial Code (Code de commerce) and Article 223-16 of the General Regulations of French Autorité des Marchés Financiers (AMF)) on January 31, 2026.
Listing place: Euronext Paris
ISIN code: FR0012634822
Website: www.maatpharma.com
Date
Total number of shares comprising the share capital
Total number of
theoretical voting rights (1)
Total number of effective voting rights (2)
01/31/26
18,847,475
18,847,475
18,833,820
(1) In accordance w...
|
|
|
03.02.26 - 17:39
|
TAGESVORSCHAU: Termine am 4. Februar 2026 (DPA-AFX)
|
|
|
FRANKFURT (dpa-AFX) - Wirtschafts- und Finanztermine am Mittwoch, den 4. Februar 2026^TERMINE UNTERNEHMEN06:45 CHE: UBS, Jahreszahlen07:00 CHE: Novartis, Jahreszahlen07:00 FRA: Credit Agricole, Jahreszahlen07:00 NOR: ......
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
